2023-09-28 17:00:00
Basilea’s Ceftobiprole Shows Promising Results in Phase III Study for Bacterial Bloodstream Infection
Allschwil-based pharmaceutical company, Basilea, announced on Thursday the positive results from the phase III study Eradicate, which examined the effectiveness of the antibiotic ceftobiprole in treating Staphylococcus aureus bacteremia (SAB) in adult patients. SAB is a severe bacterial bloodstream infection caused by Staphylococcus aureus.
According to Basilea, Eradicate was the largest approval study conducted for SAB to date. The study showed that ceftobiprole demonstrated a comparable clinical benefit to daptomycin, a commonly used antibiotic for the treatment of SAB.
Thomas Holland, the study leader from the Duke University School of Medicine, emphasized the urgent need for new therapies in this area. He stated, “No new antibiotic has been approved for the treatment of Staphylococcus aureus bacteremia in over 15 years.” With an estimated 120,000 cases per year in the United States alone, SAB is a common bloodstream infection that often leads to severe disease and high mortality rates.
In August, Basilea submitted an application for US approval of ceftobiprole. The positive results from the Eradicate study provide further support for the potential of ceftobiprole as a much-needed treatment option for SAB patients.
Upon the announcement, Basilea’s shares temporarily rose by 0.24 percent to CHF 41.10 on the SIX stock exchange.
This development is promising news for patients suffering from SAB, as it brings hope for improved treatment options and potentially better outcomes. Basilea awaits the approval decision for ceftobiprole in the United States, which could bring relief to many patients in need.]
#Basilea #shares #premiums #Basilea #publishes #data #antibiotic #ceftobiprole #renowned #journal